Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer
Status:
Terminated
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate cleavage products of the urokinase
plasminogenactivator receptor (uPAR) in plasma from patients with castration resistant
prostate cancer as a predictive marker of response to abiraterone.